Brand-Name Drug Companies Paying Generic Makers to Stay Out of Market
Leibowitz said, "Until recently, payments by brand-name companies to generics were the exception, but now they're the rule," adding, "They appear to be a new way to do business, and that's very troubling. Hopefully the Supreme Court will take our case and reverse." The Pharmaceutical Research and Manufacturers of America and the Generic Pharmaceutical Association declined to comment on Leibowitz's remarks or the FTC report (Washington Post, 4/24).
沒有留言:
張貼留言